Sarepta Therapeutics, Inc. (0L35.L)
- Simply Wall St.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Is Expected To Breakeven In The Near Future
With the business potentially at an important milestone, we thought we'd take a closer look at Sarepta Therapeutics...
- Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2023
Biotechs that utilize gene editing -- a set of techniques allowing scientists to modify an organism's DNA -- have the potential to help revolutionize medicine by developing innovative treatments for otherwise incurable illnesses. Let's consider two biotechs looking to make use of gene editing to develop breakthrough therapies: CRISPR Therapeutics (NASDAQ: CRSP) and Sarepta Therapeutics (NASDAQ: SRPT).
- Business Wire
Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
SOMERSET, N.J. & CAMBRIDGE, Mass., January 05, 2023--Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, and Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dy
